JOHNSON KRISTINA M 4

What Happened

• Kristina M. Johnson, a director of Infleqtion, Inc. (ticker INFQ, formerly Churchill Capital Corp X), was credited with two awards on Feb 13, 2026: 33,120 shares of common stock and 373,458 shares described as derivative securities. No cash price was reported for these items; they were issued in connection with the merger/recapitalization that closed as described in the filing.
• The 373,458 derivative shares represent common stock issued upon conversion of the company’s Series C-1 preferred stock pursuant to the merger. The 33,120 shares and the converted/derivative shares were received rather than bought or sold.

Key Details

• Transaction date: 2026-02-13; Filing date (Form 4): 2026-02-18 (filed five days after the reported transaction).
• Transaction codes: A (Award/Grant/Other Acquisition); price per share: N/A.
• Shares owned after the transaction: Not specified in the filing.
• Notable footnotes from the filing:
  • F1: Shares issued pursuant to the Agreement and Plan of Merger and Reorganization dated Sept 8, 2025 (company renamed Infleqtion).
  • F2: Derivative shares issued upon conversion of Series C-1 preferred stock.
  • F3: Some holdings are held directly by Catalyzer Ventures, LP Fund I; Dr. Johnson may be deemed to beneficially own those via voting/investment power.
  • F4: A vesting schedule applies to certain awards (monthly vesting of 1/36 beginning June 1, 2024).
  • F5: Legacy stock options were converted into Issuer options with the same terms due to the merger.
• Timing note: Form 4s are generally required within two business days of a transaction; this filing was submitted five days after the transaction date.

Context

• These entries reflect merger-related conversions and awards, not open-market purchases or insider sales. Such merger-driven issuances are typically administrative and do not by themselves indicate deliberate buy/sell market timing by the insider.
• The derivative entry reflects conversion of preferred shares into common stock; some shares remain subject to vesting and some are held via an entity (Catalyzer) over which Dr. Johnson has influence, which may affect beneficial ownership reporting.